FDA says this weight loss drug shortage is over, but patients worry about cost and availability

For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news.

"I had an anxiety attack," said Maria Galindo, who has lost 60 pounds since starting the drug. "I actually was sitting there, I was in the middle of a meeting and then I read an email that our doctor sent and my face got completely numb."

The 35-year-old mom is one of many patients taking a compounded version of tirzepatide produced by a pharmacy while Eli Lilly's brand-name versions, Zepbound and Mounjaro, have been in short supply.